employee
Moscow, Russian Federation
employee
employee
employee
Moscow, Russian Federation
GRNTI 58.31 Применение изотопов и ионизирующих излучений
Purpose: To determine the diagnostic capabilities of body scan (BS) and SPECT/CT in the diagnosis of various variants of bone metastases (BM). Material and methods: The data of 37 patients with BM of breast cancer (20 patients), prostate cancer (7 patients) and other tumors various localization (10 patients) were analyzed. The study was carried out in two stages: first, BS was performed, 3 hours after intravenous introduction of an osteotropic radiopharmaceutical labeled with 99mTc (technephor or phosphotech), followed by SPECT/CT of the selected zone of interest. All studies were performed on a combined system Symbia T2 (Siemens) with a 2-slice low dose CT. Results: With BS the foci of the tumor lesion were identified in 33 cases, and in SPECT/CT in 37 cases. There were detected 159 BM (21 sites: 0.4–0.9, 59 sites: 1.0–1.9, 79 sited: 2.0–4.5 cm). The total detectable incidence of metastases with BS was 66.0 % (105 BM) of all metastases detected in comparison with SPECT/CT (159 BM). Detectability with BS increased with increasing size of detectable foci. Foci less than 1 cm are detected in isolated case (1 from 21 cases). Metastases measuring from 1 cm to 1.9 cm are detected only in 52.5 % of cases (31 from 59 cases). The detectability of large metastases (2 cm or more) with BS (92.4 %) approaches the SPECT/CT (100 %) – 73 from 79 cases. There were detected with BS 27 osteoblastic BM in comparison 56 BM with SPECT/CT (48.2 %). The detectability with BS of mixed BM (76.3 %) and octeolitic BM (75.4 %) showed no differences. Firstly it can be explained by a predominance of smaller osteoblastic foci, and secondly reparative processes in metastases, accompanied by reduction of the radiopharmaceutical. The correction of the conclusion of the BS was required just in 24 cases: in 8 cases, when the BS was marked overdiagnosis, 16 – underdiagnosis. However, BS does not lose its value as a screening. In one case, even if BS has been revealed metastasis, it is not yet accompanied by destruction of bone tissue. Despite such significant differences in diagnostic accuracy of BS and SPECT/CT, BS proved to be uninformative only in 2 cases: when undetected metastases without primary tumor identified, and in the case of the screening of metastasis the accumulation of the radiopharmaceutical in the bladder. In 2 other cases, the lack of accumulation of the radiopharmaceutical was determined by the reparation that can only be considered conditionally uninformative. However, SPECT/CT shows clear advantages in the visualization of bone metastases due to computed tomography, allowing to estimate the structure of bone tissue. In 9 cases even to SPECT-slices metastases were not accompanied by pathological accumulation of the radiopharmaceutical. Conclusion: SPECT/CT is a highly informative method for detecting bone metastases, the use of which allows reducing the time of examination and dose irradiation of patients due to the rejection of additional radiological procedures. In addition, SPECT/CT at the same time allows differential diagnosis of structural and metabolic bone changes, which increases both the accuracy of primary diagnosis and control of treatment.
SPECT/CT, bone scintigraphy, bone metastases
Метастазы в костях являются важным прогностическим фактором опухолевого процесса. И, несмотря на то, что в последнее время достигнут значимый прогресс в диагностике и лечении костных метастазов, тем не менее, метастатическое поражение костей остаётся значимой проблемой.
1. Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;(4):87-93. DOI: 10.2147/CLEP.S28339.
2. Jensen AØ, Jacobsen JB, Nørgaard M, et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer. 2011;11:29. DOI: 10.1186/1471-2407-11-29.
3. Kondratiev VB, Martyniuk VV, Li LA. Metastases in the bone: complicated forms, hypercalcemia, spinal cord compression syndrome, drug treatment. Practical Oncology. 2000;(2):41-45. (In Russ.).
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342. DOI: 10.1038/nature01658.
5. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Research. 2005;15:57-62. DOI: 10.1038/sj.cr.7290266.
6. Heindel W, Gübitz R, Vieth V, et al. The diagnostic imaging of bone metastases. Dtsch. Arztebl. Int. 2014;111(44):741-747. DOI: 10.3238/arztebl.2014.0741.
7. Krzhivitsky PI, Kanaev SV, Novikov SN, et al. SPECT-CT in the diagnosis of metastatic skeletal lesion. Problems in Oncology. 2014;60(1):56-63. (In Russ.).
8. Laryukov AV, Laryukova EK. Modern possibilities of methods of radiation and nuclear diagnostic for detection of bone metastases in non-small cell lung carcinoma. Practical Medicine. 2016;93(1):112-117. (In Russ.).
9. Löfgren J, Mortensen J, Loft A, et al. Diagnosing bone metastases. Pilot data from a prospective study comparing [99mTc]-MDP planar bone scintigraphy, whole body SPECT/CT, [18F]-fluoride PET/CT and [18F]-fluoride PET/MRI. J Nucl Med. 2013;54, Suppl. 2:93-102.
10. Pagani O, Senkus E, Wood W. et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102(7):456-463. DOI: 10.1093/jnci/djq029.
11. Ryzhkov AD, Shiryaev SV, Odzharova AA, et al. 99mTc-labelled Phosphonate Metastases Bone Scintigraphy. Med Radiol and Radiation Safety. 2007;52(4):62-68. (In Russ.).
12. Ryzhkov AD, Ivanov SM, Shiryaev SV, et al. SPECT/CT radiation in treatment of bone metastases of osteosarcoma. Problems in Oncology. 2016;62(5):654-659.
13. Krylov VV, Kochetova TYu, Voloznev LV. Radionuclide therapy for bone metastases: new opportunities. Problems in Oncology. 2015;61(1):14-19.
